Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users

Medicine (United States)

Volumn 95, Issue 26, 2016, Pages

  Gamble, John Michael ^a   Thomas, Jamie M ^a   Twells, Laurie K ^a,b   Midodzi, William K ^b   Majumdar, Sumit R ^c  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

antidiabetic drugs; cardiovascular diseases; cohort studies; dipeptidyl peptidase IV inhibitors; mortality; sulfonylurea compounds; type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; INCRETIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MORTALITY RATE; MORTALITY RISK; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; MORTALITY; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84978686237     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003995     Document Type: Article

References (32)

1. Canadian Diabetes Association Clinical Expert, CommitteeCanadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2013;37 (Suppl 1):1-227
2. Canadian Agency for Drugs and Technologies in Health. Current Utilization of Second and Third-Line Therapies in Patients with Type 2 Diabetes. Ottawa:2010
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79
4. Gamble JM, Clarke A, Myers KJ, et al. Incretin-based medications for type 2 diabetes: an overview of reviews. Diabetes Obes Metab 2015; 17:649-58
5. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012;30:e146-55
6. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369: 1327-35
7. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin, cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
8. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373: 232-42
9. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:2067-76
10. Eurich DT, Simpson S, Senthilselvan A, et al. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study. BMJ 2013;346:f2267
11. Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis. Diabetes Obes Metab 2013;15:55-61
12. Morgan CL, Poole CD, Evans M, et al. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 2012;97:4605-12
13. Morgan CL, Mukherjee J, Jenkins-Jones S, et al. Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and allcause mortality. Diabetes Obes Metab 2014;16:977-83
14. Yu OHY, Yin H, Azoulay L. The combination of dpp-4 inhibitors versus sulfonylureas with metformin after failure of first-line treatment in the risk for major cardiovascular events and death. Can J Diabetes 2015;39:383-9
15. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure. JACC Heart Fail 2014;2:573-82
16. Ou S-M, Shih C-J, Chao P-W, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 2015;163:663-72
17. Rodriguez LA, Gutthann SP. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45: 419-25
18. Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9
20. Williams T, Van Staa T, Puri S, et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012;3:89-99
21. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010;60:e128-36
22. Pöge U, Gerhardt T, Palmedo H, et al. MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005;5:1306-11
23. Gallwitz B. Preclinical and clinical data on extraglycemic effects of GLP-1 receptor agonists. Rev Diabet Stud 2009;6:247-59
24. Inzucchi SE, McGuire DK. New drugs for the treatment of diabetes: part II: incretin-based therapy and beyond. Circulation 2008;117:574-84
25. Abdelmoneim AS, Eurich DT, Light PE, et al. Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. Diabetes Obes Metab 2015;17:523-32
26. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373: 2247-57
27. Yu OHY, Filion KB, Azoulay L, et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care 2015;38:277-84
28. Patorno E, Everett B, Goldfine A, et al. Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study. Diabetes Obes Metab 2016; online early May 2, 2016. doi: 10.1111/dom.12665
29. Mogensen UM, Andersson C, Fosbl EL, et al. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus-A retrospective nationwide study. Diabetes Obes Metab 2014;16:1001-8
30. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-5
31. Paul SK, Klein K, Maggs D, et al. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol 2015;14:10
32. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53